Deutsche Bank maintained its sell rating and 11,500p price target on AstraZeneca shares despite positive phase III trial results presented at the ASCO 2026 conference. The EMERALD-3 trial showed a 30% reduction in disease progression risk for a liver cancer immunotherapy combo, but regulatory approval remains uncertain. The bank also highlighted concerns about AstraZeneca's breast cancer drug camizestrant and noted the absence of AstraZeneca from ASCO's plenary session for the first time since 2018. Looking ahead, 2027 could bring key pipeline catalysts with several phase III readouts expected, while early sales of the new hypertension drug Baxfendy have been mixed.
AstraZeneca PLC will announce its Q2 2026 earnings on July 27, following a strong Q1 with 12.5% revenue growth to $15.29 billion. Key growth driver Enhertu saw a 39.4% year-over-year revenue increase, reaching $831 million, and recently gained EU app...
AstraZeneca has agreed to pay $600 million upfront and up to $1.5 billion total for global rights to Zegfrovy, a lung cancer pill developed by China's Dizal Pharmaceutical. The drug targets non-small cell lung cancer with a specific genetic mutation ...
AstraZeneca has agreed to pay $600 million upfront, with up to $900 million more based on milestones, to acquire global rights to Zegfrovy, a lung cancer pill developed by China's Dizal Pharmaceutical. The drug targets non-small cell lung cancer pati...
HSBC downgraded AstraZeneca from 'buy' to 'hold' following the failure of its Wainua phase III trial for a heart disease treatment, which missed its primary endpoint. This trial was a major part of HSBC's positive outlook, and its failure has led to ...
UBS maintains a 'buy' rating on AstraZeneca ahead of its Q2 results due on July 27, expecting solid performance but no increase in full-year guidance. The bank forecasts 2026 revenue of $63.3 billion and core earnings per share of $9.48, with a margi...
